ABBV
Price
$198.86
Change
+$2.56 (+1.30%)
Updated
Aug 7 closing price
Capitalization
322.43B
77 days until earnings call
BIIB
Price
$127.75
Change
-$5.14 (-3.87%)
Updated
Aug 7 closing price
Capitalization
31.34B
75 days until earnings call
Interact to see
Advertisement

ABBV vs BIIB

Header iconABBV vs BIIB Comparison
Open Charts ABBV vs BIIBBanner chart's image
ABBVIE
Price$198.86
Change+$2.56 (+1.30%)
Volume$4.68M
Capitalization322.43B
Biogen
Price$127.75
Change-$5.14 (-3.87%)
Volume$1.72M
Capitalization31.34B
ABBV vs BIIB Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. BIIB commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BIIB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (ABBV: $198.86 vs. BIIB: $127.75)
Brand notoriety: ABBV and BIIB are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 82% vs. BIIB: 127%
Market capitalization -- ABBV: $322.43B vs. BIIB: $31.34B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. BIIB’s [@Pharmaceuticals: Major] market capitalization is $31.34B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileBIIB’s FA Score has 0 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • BIIB’s FA Score: 0 green, 5 red.
According to our system of comparison, ABBV is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 6 bullish, 3 bearish.
  • BIIB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than BIIB.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +5.21% price change this week, while BIIB (@Pharmaceuticals: Major) price change was -0.20% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.43%. For the same industry, the average monthly price growth was +6.77%, and the average quarterly price growth was +13.43%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

BIIB is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than BIIB($31.3B). ABBV has higher P/E ratio than BIIB: ABBV (66.46) vs BIIB (26.95). ABBV YTD gains are higher at: 14.992 vs. BIIB (-16.460). ABBV has higher annual earnings (EBITDA): 17.2B vs. BIIB (2.04B). ABBV has more cash in the bank: 12.8B vs. BIIB (1.05B). BIIB has less debt than ABBV: BIIB (7.34B) vs ABBV (59.4B). ABBV has higher revenues than BIIB: ABBV (54.3B) vs BIIB (9.84B).
ABBVBIIBABBV / BIIB
Capitalization322B31.3B1,029%
EBITDA17.2B2.04B844%
Gain YTD14.992-16.460-91%
P/E Ratio66.4626.95247%
Revenue54.3B9.84B552%
Total Cash12.8B1.05B1,219%
Total Debt59.4B7.34B809%
FUNDAMENTALS RATINGS
ABBV vs BIIB: Fundamental Ratings
ABBV
BIIB
OUTLOOK RATING
1..100
717
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
1472
PRICE GROWTH RATING
1..100
3460
P/E GROWTH RATING
1..100
1795
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIIB's Valuation (87) in the Biotechnology industry is in the same range as ABBV (89) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (72) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than BIIB’s over the last 12 months.

ABBV's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as BIIB (60) in the Biotechnology industry. This means that ABBV’s stock grew similarly to BIIB’s over the last 12 months.

ABBV's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (95) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVBIIB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
42%
Bearish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
70%
MACD
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
50%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
58%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
69%
Advances
ODDS (%)
Bullish Trend 3 days ago
56%
Bullish Trend 3 days ago
53%
Declines
ODDS (%)
Bearish Trend 8 days ago
45%
Bearish Trend 9 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
30%
Bullish Trend 1 day ago
43%
Aroon
ODDS (%)
Bullish Trend 1 day ago
62%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IQDG38.580.38
+0.99%
WisdomTree International Qual Div Gr ETF
MLPD25.270.01
+0.05%
Global X MLP & Engy Infras Cov Cll ETF
IBHI23.55N/A
N/A
iShares iBonds 2029 Term HY & Inc ETF
VOOG410.96-1.29
-0.31%
Vanguard S&P 500 Growth ETF
PXI42.13-0.18
-0.43%
Invesco Dorsey Wright Energy MomentumETF

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-3.87%
PFE - BIIB
57%
Loosely correlated
+1.25%
MRK - BIIB
48%
Loosely correlated
+1.17%
NVS - BIIB
46%
Loosely correlated
+2.13%
ABBV - BIIB
46%
Loosely correlated
+1.30%
GSK - BIIB
45%
Loosely correlated
+2.26%
More